Search clinical trials for: Terelizumab (aka Tislelizumab)

Total 2666 results

Daping Hospital and the Research Institute of Surgery...

Recruiting

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Gastric Cancer | Rectal Cancer | Chemotherapy Effect | Radiotherapy | Immunotherapy

China
Second Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Eye & ENT Hospital of Fudan University

Not yet recruiting

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Colon Cancer | Immunotherapy | MSI-H | Adjuvant Therapy

China
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Terminated

Treatment With hOKT3gamma1(Ala-Ala) in T1DM

Diabetes Mellitus, Type 1

United States
Zhejiang Cancer Hospital

Recruiting

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Locally Advanced Gastric Cancer

China
Yixing People's Hospital

Recruiting

Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery

Gastric Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Colorectal Cancer | Liver Metastases

China
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile...

Completed

Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Hoffmann-La Roche

Completed

A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting (PRO-MSACTIVE)

Multiple Sclerosis

France
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
First Affiliated Hospital of Zhejiang University
BeiGene (Beijing) Co., Ltd

Recruiting

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

BCLC Stage C Hepatocellular Carcinoma

China
Fudan University

Not yet recruiting

Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

PFS
Gang Wu

Not yet recruiting

Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

Carcinoma, Non-Small Cell Lung
Huihua Xiong

Recruiting

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study (UTILIZABLE)

TNBC - Triple-Negative Breast Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Stomach Cancer

China
Thammasat University

Completed

Comparison of Functional Recovery Between Mobile Bearing Unicompartmental Knee Arthroplasty and Total Knee Arthroplasty

Patient Reported Outcome Measure

Thailand
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC (HNC-SYSU-001)

Head and Neck Squamous Cell Carcinoma | Oral Cancer

China
Ottawa Hospital Research Institute

Withdrawn

Unicompartmental Knee Arthroplasty (UKA) Versus Total Knee Arthroplasty (TKA) of Medial Osteoarthritis

Osteoarthritis, Knee

Canada
Peking University Cancer Hospital & Institute

Recruiting

Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Non-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential Chemoradiation

China
Chen Xiaoping

Not yet recruiting

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

HCC
Medacta USA

Withdrawn

Bilateral Total Knee Arthroplasty vs Unicompartment Arthroplasty Retrospective and Clinical Outcome Study

Osteoarthritis

United States
Alexion Pharmaceuticals

Completed

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Coronary Artery Bypass Graft | Cardio-pulmonary Bypass

United States, Canada
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Shanghai Gopherwood Biotech Co., Ltd.

Recruiting

Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Malignant Solid Tumors

China
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites

China
Peter MacCallum Cancer Centre, Australia

Recruiting

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

Cancer

Australia
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
Hvidovre University Hospital
Parker Research Institute; Frederiksberg University Hospital

Recruiting

Surgery Induced Trauma After Total Versus Medial Unicompartmental Knee Arthroplasty (SITA) (SITA)

Arthritis | Knee Osteoarthritis | Surgery | Total Knee Arthroplasty | Unicompartmental Knee Arthroplasty

Denmark
Fudan University

Recruiting

Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy (Castle06(BC))

Metastatic Breast Cancer in the Liver

China
Fudan University

Active, not recruiting

Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Fudan University

Recruiting

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Nasopharyngeal Carcinoma

China
Theramab LLC

Completed

Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms (TAB08)

Solid Tumors

Russian Federation
Sichuan Cancer Hospital and Research Institute

Recruiting

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC (ETNT)

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital
Henan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaborators

Recruiting

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
BeiGene

Completed

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Locally Advanced or Metastatic Urothelial Bladder Cancer

Korea, Republic of, China
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
BeiGene

Completed

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
Ruijin Hospital

Recruiting

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Peking Union Medical College Hospital

Recruiting

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Cervical Cancer Recurrent

China
Hebei Medical University Fourth Hospital

Recruiting

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Lung Adenocarcinoma

China
Fudan University

Not yet recruiting

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study (TEMPLATE)

Triple Negative Breast Cancer

China
XIANG YANQUN

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Recruiting

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (TALENT)

Recurrent Hepatocellular Carcinoma

China
University College, London
BeiGene

Not yet recruiting

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma (RATiFY)

Hodgkin Lymphoma
MacroGenics
Eli Lilly and Company

Terminated

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States, Israel, United Kingdom, Poland, France, Germany, Belgium, Finland, India, Ukraine, Spain, Czechia, Italy, Mexico, Netherlands, Romania
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China

3

Subscribe